scholarly journals Higher Testosterone Levels Are Associated with Less Loss of Lean Body Mass in Older Men

2011 ◽  
Vol 96 (12) ◽  
pp. 3855-3863 ◽  
Author(s):  
Erin S. LeBlanc ◽  
Patty Y. Wang ◽  
Christine G. Lee ◽  
Elizabeth Barrett-Connor ◽  
Jane A. Cauley ◽  
...  
Keyword(s):  
Lean Body Mass ◽  
Body Mass ◽  
Older Men ◽  
Testosterone Levels

scholarly journals Differences in the Apparent Metabolic Clearance Rate of Testosterone in Young and Older Men with Gonadotropin Suppression Receiving Graded Doses of Testosterone

2006 ◽  
Vol 91 (11) ◽  
pp. 4669-4675 ◽  
Author(s):  
Andrea D. Coviello ◽  
Kishore Lakshman ◽  
Norman A. Mazer ◽  
Shalender Bhasin
Keyword(s):  
Lean Body Mass ◽  
Body Mass ◽  
Young Men ◽  
Serum Testosterone ◽  
Older Men ◽  
Total Testosterone ◽  
Metabolic Clearance ◽  
Clearance Rates ◽  
Testosterone Levels ◽  
Age Related

Abstract Background: Recently we found that testosterone levels are higher in older men than young men receiving exogenous testosterone. We hypothesized that older men have lower apparent testosterone metabolic clearance rates (aMCR-T) that contribute to higher testosterone levels. Objective: The objective of the study was to compare aMCR-T in older and young men and identify predictors of aMCR-T. Methods: Sixty-one younger (19–35 yr) and 60 older (59–75 yr) men were given a monthly GnRH agonist and weekly testosterone enanthate (TE) (25, 50, 125, 300, or 600 mg) for 5 months. Estimated aMCR-T was calculated from the amount of TE delivered weekly and trough serum testosterone concentrations, corrected for real-time absorption kinetics from the im testosterone depot. Results: Older men had lower total (316 ± 13 vs. 585 ± 26 ng/dl, P < 0.00001) and free testosterone (4 ± 0.1 vs. 6 ± 0.3 ng/dl, P < 0.00001) and higher SHBG (52 ± 3 vs. 33 ± 2 nmol/liter, P < 0.00001) than younger men at baseline. Total and free testosterones increased with TE dose and were higher in older men than young men in the 125-, 300-, and 600-mg dose groups. aMCR-T was lower in older men than young men (1390 ± 69 vs. 1821 ± 102 liter/d, P = 0.006). aMCR-T correlated negatively with age (P = 0.0007), SHBG (P = 0.046), and total testosterone during treatment (P = 0.02) and percent body fat at baseline (P = 0.01) and during treatment (P = 0.004). aMCR-T correlated positively with lean body mass at baseline (P = 0.03) and during treatment (P = 0.01). In multiple regression models, significant predictors of aMCR-T included lean body mass (P = 0.008), percent fat mass (P = 0.009), and SHBG (P = 0.001). Conclusions: Higher testosterone levels in older men receiving TE were associated with an age-related decrease in apparent testosterone metabolic clearance rates. Body composition and SHBG were significant predictors of aMCR-T.

scholarly journals Effects of Testosterone Replacement with a Nongenital, Transdermal System, Androderm, in Human Immunodeficiency Virus-Infected Men with Low Testosterone Levels1

1998 ◽  
Vol 83 (9) ◽  
pp. 3155-3162
Author(s):  
Shalender Bhasin ◽  
Thomas W. Storer ◽  
Nancy Asbel-Sethi ◽  
Amy Kilbourne ◽  
Ron Hays ◽  
...  
Keyword(s):  
Placebo Group ◽  
Cell Count ◽  
Lean Body Mass ◽  
Body Mass ◽  
Fat Free Mass ◽  
Testosterone Replacement ◽  
Red Cell ◽  
Testosterone Levels ◽  
Red Cell Count ◽  
Group Change

Although weight loss associated with human immunodeficiency virus (HIV) infection is multifactorial in its pathogenesis, it has been speculated that hypogonadism, a common occurrence in HIV disease, contributes to depletion of lean tissue and muscle dysfunction. We, therefore, examined the effects of testosterone replacement by means of Androderm, a permeation-enhanced, nongenital transdermal system, on lean body mass, body weight, muscle strength, health-related quality of life, and HIV-disease markers. We randomly assigned 41 HIV-infected, ambulatory men, 18–60 yr of age, with serum testosterone levels below 400 ng/dL, to 1 of 2 treatment groups: group I, two placebo patches (n = 21); or group II, two testosterone patches designed to release 5 mg testosterone over 24 h. Eighteen men in the placebo group and 14 men in the testosterone group completed the 12-week treatment. Serum total and free testosterone and dihydrotestosterone levels increased, and LH and FSH levels decreased in the testosterone-treated, but not in the placebo-treated, men. Lean body mass and fat-free mass, measured by dual energy x-ray absorptiometry, increased significantly in men receiving testosterone patches [change in lean body mass,+ 1.345 ± 0.533 kg (P = 0.02 compared to no change); change in fat-free mass, +1.364 ± 0.525 kg (P = 0.02 compared to no change)], but did not change in the placebo group [change in lean body mass, 0.189 ± 0.470 kg (P = NS compared to no change); change in fat-free mass, 0.186 ± 0.470 kg (P = NS compared to no change)]. However, there was no significant difference between the 2 treatment groups in the change in lean body mass. The change in lean body mass during treatment was moderately correlated with the increment in serum testosterone levels (r = 0.41; P = 0.02). The testosterone-treated men experienced a greater decrease in fat mass than those receiving placebo patches (P = 0.04). There was no significant change in body weight in either treatment group. Changes in overall quality of life scores did not correlate with testosterone treatment; however, in the subcategory of role limitation due to emotional problems, the men in the testosterone group improved an average of 43 points of a 0–100 possible score, whereas those in the placebo group did not change. Red cell count increased in the testosterone group (change in red cell count, +0.1 ± 0.1 1012/L) but decreased in the placebo group (change in red cell count, −0.2 ± 0.1 1012/L). CD4+ and CD8+ T cell counts and plasma HIV copy number did not significantly change during treatment. Serum prostate-specific antigen and plasma lipid levels did not change in either treatment group. Testosterone replacement in HIV-infected men with low testosterone levels is safe and is associated with a 1.35-kg gain in lean body mass, a significantly greater reduction in fat mass than that achieved with placebo treatment, an increased red cell count, and an improvement in role limitation due to emotional problems. Further studies are needed to assess whether testosterone supplementation can produce clinically meaningful changes in muscle function and disease outcome in HIV-infected men.

Relationships between central arterial stiffness, lean body mass, and absolute and relative strength in young and older men and women

2017 ◽  
Vol 38 (4) ◽  
pp. 676-680 ◽  
Author(s):  
Christopher A. Fahs ◽  
Robert S. Thiebaud ◽  
Lindy M. Rossow ◽  
Jeremy P. Loenneke ◽  
Debra A. Bemben ◽  
...  
Keyword(s):  
Arterial Stiffness ◽  
Lean Body Mass ◽  
Body Mass ◽  
Older Men ◽  
Relative Strength ◽  
Men And Women ◽  
Older Men And Women

scholarly journals d-Chiro-Inositol improves testosterone levels in older hypogonadal men with low-normal testosterone: a pilot study

2021 ◽  
Vol 31 (1) ◽  
Author(s):  
Maurizio Nordio ◽  
Philip Kumanov ◽  
Alfonsina Chiefari ◽  
Giulia Puliani
Keyword(s):  
Body Mass Index ◽  
Pilot Study ◽  
Waist Circumference ◽  
Sexual Function ◽  
Body Mass ◽  
Older Men ◽  
Testosterone Replacement Therapy ◽  
Limited Information ◽  
Physical Strength ◽  
Testosterone Levels

Abstract Background Several recent journal articles report that d-chiro-inositol (DCI), primarily known as insulin second messenger, influences steroidogenesis. In particular, new evidence is arising on DCI ability to regulate aromatase expression and testosterone biosynthesis. In this regard, DCI administration could represent a good therapeutic opportunity in case of reduced levels of testosterone. Older men generally have lower testosterone concentrations than younger men, and recent randomized controlled trials have examined whether testosterone treatment might improve health outcomes in this age group. There is limited information about the safety of testosterone replacement therapy in these men, hence DCI could represent an interesting alternative for future trials. Therefore, this study aims to evaluate the effect of DCI treatment on testosterone levels in older male patient. Results Ten older men with basal low testosterone levels were enrolled in this study. Patients took 600 mg of DCI, two-times per day, for 30 days. We evaluated hormonal and glycaemic parameters, weight, waist circumference, and Body-Mass Index at baseline (T0) and after 30 days (T1). Finally, all patients also filled in the standardized International Index of Erectile Function questionnaire and performed the Handgrip test at T0 and T1. Men receiving DCI showed increased androgen and reduced oestrogen concentrations, and improved glycaemic profiles. DCI was also associated with reduced weight, Body-Mass Index, waist circumference, and improved grip strength and self-reported sexual function. All these effects led to the improvement of sexual function and physical strength. Conclusions In this pilot study, DCI treatment improved the levels of testosterone and androstenedione at the expense of oestrogens in elder men with low basal levels of these hormones without adverse effects. Trial registration Clinicaltrials.gov: D-chiroinositol Administration in Hypogonadal Males, NCT04708249

scholarly journals Effect of Protein Intake on Lean Body Mass in Functionally Limited Older Men

2018 ◽  
Vol 178 (4) ◽  
pp. 530 ◽  
Author(s):  
Shalender Bhasin ◽  
Caroline M. Apovian ◽  
Thomas G. Travison ◽  
Karol Pencina ◽  
Lynn L. Moore ◽  
...  
Keyword(s):  
Lean Body Mass ◽  
Body Mass ◽  
Protein Intake ◽  
Older Men

Allornetric Scaling of VO2 Max by Body Mass and Lean Body Mass in Older Men

1995 ◽  
Vol 3 (4) ◽  
pp. 324-331 ◽  
Author(s):  
Michael J. Davies ◽  
Gail P. Dalsky ◽  
Paul M. Vanderburgh
Keyword(s):  
Body Size ◽  
Lean Body Mass ◽  
Body Mass ◽  
Allometric Scaling ◽  
Older Men ◽  
Dual Energy ◽  
The Body ◽  
X Ray ◽  
Ratio Standards ◽  
Size Variable

This study employed allometry to scale maximal oxygen uptake (V̇O2max) by body mass (BM) and lean body mass (LBM) in healthy older men. Ratio standards (ml · kg−1· min−1) derived by dividing absolute V̇O2max (L · min−1) by BM or LBM often fail to control for the body size variable. The subjects were 73 older men (mean ±SD:age = 69.7 ± 4.3 yrs, BM = 80.2 ± 9.6 kg, height = 174.1 ± 6.9 cm). V̇O2max was assessed on a treadmill with the modified Balke protocol (V̇O2max = 2.2 ± 0.4 L · min−1). Body fat (27.7 ± 6.4%) was assessed with dual energy x-ray absorptiometry. Allometry applied to BM and V̇O2max determined the BM exponent to be 0.43, suggesting that heavier older men are being penalized when ratio standards are used. Allometric scaling applied to LBM revealed the LBM exponent to be 1.05 (not different from the ratio standard exponent of 1.0). These data suggest that the use of ratio standards to evaluate aerobic fitness in older men penalized fatter older men but not those with higher LBM.

Sign in / Sign up

Export Citation Format

Share Document